Serapha Bio is a clinical-stage biotechnology company focused on developing a novel gene therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Serapha Bio is a clinical-stage biotechnology company focused on developing a novel gene therapy for Alpha-1 Antitrypsin Deficiency (AATD). The company is developing SERP-01, an in vivo base editing therapy targeting the SERPINA1 mutation.